Maintenance of motion at L5/S1 does matter.

CENTER VALLEY, Pa., Sept. 25, 2018 /PRNewswire/ -- Aesculap Implant Systems, LLC today announced that critical long-term data will be presented by Dr. Scott Blumenthal of the Center for Disc Replacement at the Texas Back Institute during the NASS 2018 Annual Meeting (Los Angeles, CA, September 25-29, 2018). The post-hoc analysis from the activL^® Artificial Disc Investigational Device Exemption study challenges common misconceptions about the value of motion preservation at the lumbosacral junction. Two different oral podium presentations will be delivered during the NASS Annual Meeting examining the effects of range of motion on long-term clinical outcomes. This data comes one year after NASS panelists concluded that the body of evidence for lumbar total disc replacement (TDR) supports lumbar TDR as a standard of care for the treatment of discogenic chronic low back pain.

"When we began analyzing the data specific to the performance of these disc replacements at L5/S1, it became obvious that there are reasons to avoid a fusion, if possible, at this level," said Scott Blumenthal, MD. "Patients who had six degrees of motion at L5/S1 five years postoperative experienced 100% success in their VAS pain score improvement and for every two degrees of motion were more likely to have Oswestry success. That says a lot about the correlation between motion, pain and function and why we do what we do."

The long-term data will also report on the long-term range of motion outcomes between first and current generation lumbar disc replacement designs and its impact on clinical outcomes and adjacent segment disease. On average, activL^® Artificial Disc patients maintain their preoperative range of motion (6.6° vs. 6.1°, p=0.4) while ProDisc-L patients do not (6.2° vs. 4.2°, p=0.02). This drop off in range of motion has been correlated to increased progression of adjacent segment disease (8.8% vs. 19%, p=0.05).

Details of the NASS oral presentations:

Impact of Range of Motion on Patient Outcomes Five Years Following Lumbar TDR at L5-S1

Impact of Range of Motion on Progression of Adjacent Segment Disease: Disc versus Disc

To learn more about the activL® Artificial Disc, please visit Aesculap Implant Systems at Booth #1101 in the NASS 2018 Exhibit Hall.

About Aesculap Implant Systems, LLC
Aesculap Implant Systems, LLC, a B. Braun company, is part of a 175-year-old global organization focused on meeting the needs of the changing healthcare environment. Through close collaboration with its customers, Aesculap Implant Systems develops advanced spine and orthopaedic implant technologies to treat complex disorders of the spine, hip and knee. Aesculap Implant Systems strives to deliver products and services that improve the quality of patients' lives. For more information, call 800-234-9179 or visit aesculapimplantsystems.com.

SOURCE Aesculap Implant Systems, LLC

Related Links

http://aesculapimplantsystems.com